Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study
Saad Z. Usmani(Levine Cancer Institute), Alfred L. Garfall(University of Pennsylvania), Niels W.C.J. van de Donk, Hareth Nahi(Karolinska University Hospital), Jesús F. San Miguel(Clinica Universidad de Navarra), Albert Oriol(Institut Català d'Oncologia), Laura Rosiñol(Hospital Clínic de Barcelona), Ajai Chari(Icahn School of Medicine at Mount Sinai), Manisha Bhutani(Levine Cancer Institute), Lionel Karlin(Hôpital Lyon Sud), Lotfi Benboubker(Centre Hospitalier Universitaire de Tours), Lixia Pei(Janssen (United States)), Raluca Verona(Janssen (United States)), Suzette Girgis(Janssen (United States)), Tara Stephenson(Janssen (United States)), Yusri Elsayed(Janssen (United States)), Jeffrey R. Infante(Janssen (United States)), Jenna D. Goldberg(Janssen (United States)), Arnob Banerjee(Janssen (United States)), María‐Victoria Mateos(Centro de Investigación Biomédica en Red de Cáncer), Amrita Krishnan(City of Hope)
Cited by 308
Abstract
Related Papers
No related papers found
Powered by citation graph analysis